NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
SoftBank to Invest €75 Billion in France AI Data Center Expansion by 2031 
Nvidia and Microsoft to Launch AI-Powered Windows PCs at Computex 2026 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Trump Adviser’s Investment in Thrive Capital Draws Scrutiny Over Federal Contracts 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Universal Music Group Rejects Pershing Square Takeover Proposal 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
